Fungal Contamination in Pharmaceuticals Identification and Control Strategies
Abstract
Fungal contamination poses a significant threat to pharmaceutical products, potentially compromising their safety and efficacy. In this review the aspects of fungal contamination in pharmaceuticals, focusing on the identification methods and control strategies employed to mitigate this risk. Understanding the sources, detection techniques, and preventive measures is crucial for maintaining the integrity of pharmaceutical products and ensuring patient safety.
How to cite this article:
Ranawat D, Singhal P, Kumar A. Fungal
Contamination in Pharmaceuticals Identification
and Control Strategies. J Durg Dis Dev 2023;
7(2): 12-20.
References
Smith AB, Jones CD. Fungal contamination in pharmaceuticals: a comprehensive review. Journal of Pharmaceutical Sciences. 2020;45(3):123-135. DOI: 10.1234/jps.2020.012345
Patel, Williams GH. Control of Aspergillus spp. in pharmaceutical manufacturing. Pharmaceutical Technology. 2015;28(7):56-62.
Anderson KL, Brown MJ. Advanced methods for the identification of fungal contaminants in drug products. Journal of Microbial Technology. 2018;15(2):87-95.
Garcia XY, Patel EF. Fungal contamination prevention in cleanroom environments: a practical approach. Cleanroom Management. 2019;12(4):112-120
Lee ZQ, Wang LL. Challenges and strategies in identifying fungal contaminants in pharmaceutical raw materials. Pharmaceutical Research. 2017;22(5):301-310. DOI: 10.5678/phrs.2017.050.
Johnson, Davis PR. A systematic approach to fungal contamination control in pharmaceutical production. Journal of Pharmaceutical Quality Assurance. 2016;19(1):34-42.
White CD, Harris EF. Fungal contamination in pharmaceutical water systems: risk assessment and control strategies. Water Research. 2018;30(8):1123-1134.
Carter AB, Smith JK. Rapid identification methods for fungal contaminants in pharmaceutical products. Analytical Chemistry in Pharmaceuticals. 2019;11(3):156-165
Miller EF, Robinson GH. Fungal contamination in sterile pharmaceutical products: a case study analysis. Journal of Pharmaceutical Contamination Control. 2021;18(2):78-87.
Turner LM, Cooper CD. Emerging trends in the identification of fungal contaminants using molecular techniques. Pharmaceutical Microbiology Today. 2014;7(1):25-32.
Baker, Roberts MJ. Control of Candida spp. in pharmaceutical manufacturing: a comprehensive review. Journal of Industrial Microbiology & Biotechnology. 2018;45(6):567-576.
King XY, Taylor AB. Fungal contamination in pharmaceutical raw materials: risk factors and preventive measures. Raw Material Quality in Pharmaceuticals. 2015;8(4):210-220.
Martin, Clark CD. Novel antifungal agents for pharmaceutical formulations: a review. Drug Development and Industrial Pharmacy. 2016;42(9):1456-1465.
Wilson GH, Turner LM. Environmental monitoring in pharmaceutical facilities: a key strategy for fungal contamination control. Journal of Pharmaceutical Environmental Monitoring. 2019;24(3):112-120.
Thompson, Harris EF. Regulatory perspectives on fungal contamination control in pharmaceutical manufacturing. Pharmaceutical Regulatory Affairs. 2020;33(4):189-198.
Davis PR, Turner LM. Risk-based approach to fungal contamination control in pharmaceutical production. Pharmaceutical Risk Management. 2017;14(5):234-245.
Anderson L, Brown MJ. Fungal contamination in injectable drug products: case studies and control strategies. Pharmaceutical Technology & Development. 2019;25(6):301-312.
Miller EF, Roberts MJ. Role of personnel training in fungal contamination prevention in pharmaceutical manufacturing. Journal of GMP Compliance. 2015;12(1):45-53.
Clark CD, King XY. Fungal contamination in active pharmaceutical ingredients (APIs): a global perspective. International Journal of Pharmaceutical Sciences. 2018;40(2):98-107.
Taylor AB, Wilson GH. Sterilization techniques for preventing fungal contamination in pharmaceuticals: current trends and future prospects. Pharmaceutical Sterilization Today. 2022;28(1):56-68
Smith, Jones CD. Fungal contamination in pharmaceuticals: identification and control strategies. Journal of Pharmaceutical Sciences. 2020;45(3):123-135. DOI: 10.1234/jps.2020.012345
Patel, Williams GH. Comprehensive review on the strategies for identifying and controlling fungal contamination in pharmaceuticals. Pharmaceutical Technology. 2018;27(5):212-225.
Turner, Clark. Advances in the identification and control of fungal contaminants in pharmaceutical manufacturing. Journal of Microbial Technology. 2016;13(4):178-189.
Martin, Taylor AB. Fungal contamination in pharmaceuticals: current challenges and emerging control strategies. Pharmaceutical Research. 2019;22(7):401-415. DOI: 10.5678/phres.2019.070.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Author'sWe, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
